# A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

> **NCT07393321** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 210 (estimated)

## Conditions studied

- HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Placebo + fulvestrant
- **DRUG:** NTQ1062+Fulvestrant

## Key facts

- **NCT ID:** NCT07393321
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2028-08-31
- **Final completion:** 2031-08-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07393321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07393321, "A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07393321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*